Galapagos Suffers Record Drop as FDA Fails to Approve Drug

Bookmark
(Bloomberg) -- Belgian biotech company Galapagos NV lost about a third of its market value -- its biggest decline on record -- after the U.S. Food and Drug Administration failed to approve a rheuma...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.